196 results
8-K
EX-99.1
KA
Kineta Inc
8 Apr 24
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
4:02pm
and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
Favorable clinical safety and tolerability … cytokines and chemokines
Dose-dependent increases in activated non-classical monocytes, CD4+ and CD8+ T cells, and NK cells
Safety
No DLTs observed
8-K
EX-99.1
KA
Kineta Inc
21 Mar 24
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
4:04pm
Cancer Tumors
Efficacy
Announced positive KVA12123 monotherapy safety data from its ongoing Phase 1/2 VISTA-101 clinical trial in patients with advanced … .
· Dose-dependent increases in non-classical monocytes, CD4+ and CD8+ T cells, and NK cells.
Safety
· No dose limiting toxicities (DLTs) observed in any
8-K
EX-99.1
KA
Kineta Inc
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
cells
Safety
No DLTs observed in any patient at any dose level
No evidence of cytokine release syndrome in any patient at any dose level
“We … to be encouraged by the safety profile of KVA12123, supporting advancement to higher doses,” said Thierry Guillaudeux, Ph.D., Chief Scientific Officer
8-K
EX-99.2
lun5 84r88bs2oykck2
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
8-K
EX-99.1
qzzay
17 Jan 24
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
8:30am
8-K
EX-99.1
r0bh4mr k7
5 Jan 24
Regulation FD Disclosure
4:30pm
8-K
EX-99.2
b0c ehps5
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
gsvdzlkpza1cbbyfkr4g
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
EX-99.1
uypudofb784knq
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
EX-99.1
gk2pvv5 qp
3 Nov 23
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:02pm
8-K
EX-99.2
t1dh0 63tk
17 Oct 23
Entry into a Material Definitive Agreement
8:32am
8-K
zywftcq0cxc6pvu g2a4
17 Oct 23
Entry into a Material Definitive Agreement
8:32am
8-K
EX-99.1
8x7 nxii6f
17 Oct 23
Entry into a Material Definitive Agreement
8:32am
8-K
EX-10.1
yxt ctke3
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
8-K
EX-99.1
t06g953u
3 Oct 23
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
8:30am
8-K
q5w5pmi7 4mu8or
3 Oct 23
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
8:30am
8-K
EX-99.1
7dm 8a7yhfs53tnus6
11 Aug 23
Regulation FD Disclosure
4:08pm